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With the publication of the JUPITER
trial [1] there is now considerable interest
in measuring high-sensitivity C-reactive
protein (hsCRP). While treatment with
rosuvastatin decreased the chance of
clinically important events in the JUPI-
TER trial, does this necessarily justify
treatment based on hsCRP measure-
ments? Here, we discuss issues surround-
ing hsCRP measurements in patients.
What Is the Suggested Role for
hsCRP Measurements?
The median values for hsCRP are
2.5 mg/l (American women) and
1.5 mg/l (American men) [2]. Typical
recommendations are to measure hsCRP
in ‘‘intermediate risk’’ patients to help
classify them into either a higher or lower
risk category [3,4]. Intermediate risk is
usually, and arbitrarily, described as either
a 10%–20% [3,4] or 5%–20% [5,6] 10-
year risk of developing coronary heart
disease (CHD). It has been suggested that
hsCRP levels,1, 1–3, or .3 mg/l repre-
sent lower, moderate, and higher relative
risk of future heart disease, respectively.
How Accurate Is hsCRP
Measurement?
Between-subject standard deviation for
hsCRP measurement is 1.7 mg/l. Within-
subject standard deviation is 1.2 mg/l [7].
Clearly, within-subject standard deviation
means that a patient with a reported
hsCRP of 2 mg/l (moderate) when re-
measured could readily be placed in a low
(,1 mg/l) or high (.3 mg/l) range [7].
Some authors have therefore suggested
hsCRP needs to increase or decrease by
120% to 175% before a ‘‘real’’ change can
be considered to have occurred [8]. It has
been estimated that ‘‘in order to reduce the
intra-individual variation sufficiently, each
subject is likely to require blood samples
collected on at least 10 occasions’’ [9].
Does Measuring hsCRP Add
Value to Already Established
Risk Factors When It Comes to
Assessing CHD or
Cardiovascular Disease Risk?
Several studies have confirmed that using
hsCRP in addition to established risk
factors (age, gender, blood pressure, choles-
terol, smoking, and diabetes) does not
improve the estimation of risk of cardiovas-
cular disease (CVD) to a clinically impor-
tant degree. Folsom et al. found that
elevated hsCRP was associated with an
increased risk of CHD (hazard rate ratio
1.19, p,0.001) but that it was similar to, or
less important than, many other markers
including D-dimer (1.36), interleukin-6
(1.28), and lipoprotein-associated phospho-
lipase A2 (1.17) [10]. Wang et al. used C
statistics to assess CVD predictive models
and found age, sex, and traditional risk
factors provided 0.76 value compared to
the 0.77 value when ten different biomark-
ers (including hsCRP) were added [11].
Shah et al. also assessed the additive value
of hsCRP and found that ‘‘hsCRP does not
perform better than the Framingham risk
equation for discrimination. The improve-
ment in risk stratification or reclassification
…is small and inconsistent’’ [12].
How Does Measuring hsCRP
Affect Absolute Risk Estimates
of CVD in Individuals?
The Reynolds Risk Score [13] is an
online calculator that incorporates hsCRP
measurement with other risk factor infor-
mation (age, sex, systolic blood pressure
[SBP], smoking history, total cholesterol,
high-density lipoprotein [HDL] cholesterol,
and family history) to compute the risk (%)
of heart attack, stroke, or other major heart
disease in the next 10 years. We used two
patients, one male and one female with a
‘‘moderate’’ hsCRP level (2 mg/l), and
adjusted other factors so that they would
have an overall absolute risk estimate of
15%—in the middle of the ‘‘intermediate’’
risk category. We then changed hsCRP to
0.5, 5, or 10 mg/l to see what would
happen to their calculated risk (Table 1).
Absolute risk estimates changed by just
62% (male) and 63%–4% (female). It is
important to appreciate that the magni-
tude of these risk estimate changes are
equal to or less than the confidence
interval (CI) on the original risk estimate.
Anderson et al. noted for the Framingham
dataset that the 95% CIs for 10-year
predictions of CHD of less than 10%,
10%–20%, and 30%–40% were 61.5%–
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Reynolds et al. recently calculated the CI
of the estimates at 10%, 15%, 20%, and
30% thresholds to be 64%, 5%, 6%, and
7%, respectively [15]. It seems obvious
that refining such predictions by 62%–
4% by incorporating hsCRP measure-
ments is of little clinical relevance.
Nonetheless, if we assume the changes
in risk estimate using hsCRP are exact and
the risk estimates are actually changed by
the percentage suggested; are these chang-
es in risk estimate clinically relevant? First,
in these scenarios, one can see that none of
the revised risk estimates actually end up
recategorizing our particular patients into
a different risk category. Second, would
knowing one’s risk was 17% or 13%,
instead of 15% lead to a difference in the
decision to consider taking a drug?
Let’s assume statins produce a 25%
relative risk reduction in CVD. If a patient
has an absolute baseline risk of 17%, their
risk, if they took a statin, would decline to
12.75%, an absolute difference of 4.25%.
If their baseline risk was 15%, a statin
would lower their risk to 11.25%, an
absolute difference of 3.75%. In other
words, in this patient, if the absolute risks
were indeed different the difference in the
estimate of absolute benefit would be 0.5%
(4.25% minus 3.75%); a difference unlike-
ly to change the decision to use or not use
a statin.
Don’t Studies Show hsCRP
Measurements Reclassify
Patients into Different Risk
Categories?
Ridker et al. have shown that incorpo-
rating hsCRP ‘‘reclassifies’’ people into
different risk categories [6,16]. For instance,
14% of women and 12% of men were
recategorized from intermediate to low risk.
However, others have disputed these find-
ings and found that only 5.6% of patients
would end up being reclassified [17]. What
is likely happening in these ‘‘reclassifica-
tion’’ papers is a number of patients with
risks just above or below these arbitrary
thresholds (say an estimated 18%–19% risk)
will be bumped up or down to a different
risk category because their estimate has
now changed by 2%–3%, but these
absolute changes, as discussed above, have
little clinical relevance [13].
Does Lowering hsCRP with
Drugs Result in Improved
Cardiovascular Outcomes?
In the JUPITER trial (Justification for
the Use of Statins in Primary Prevention:
An Intervention Trial Evaluating Rosu-
vastatin), rosuvastatin was shown to re-
duce the chance of developing a clinically
important cardiovascular event. Table 2
outlines the impact of other drugs on
hsCRP and cardiovascular events. Al-
though each drug has various pharmaco-
logical effects the impact of lowering
hsCRP with medication on cardiovascular
events is consistently inconsistent.
What Were the Outcomes of
JUPITER?
The JUPITER investigators screened
almost 90,000 people to enroll 17,802 who
had an hsCRP$2 mg/l and an
LDL,3.4 mmol/l (130 mg/dl). Partici-
pants (mean age 66, median LDL of
2.8 mmol/l, average hsCRP of 4.2 mg/l)
were randomized to rosuvastatin 20 mg
daily or placebo. Based on the baseline
characteristics of these participants, using
the Reynolds risk score, the average
participant in this trial would have had a
10-year risk of approximately 10%–15%
[13]. The trial was stopped early, after a
median follow-up of 1.9 years revealed
that the combined endpoint of myocardial
infarction, stroke, or death from cardio-
vascular causes occurred in 0.9% of
participants taking rosuvastatin compared
to 1.8% of patients taking placebo.
Ideally, the effects of hsCRP on risk
assessment and treatment decisions would
be evaluated using a randomized trial with
two groups: one in which a risk assessment
included hsCRP and one that did not.
Then participants in each group would
receive a drug known to improve cardiac
outcomes at a predefined risk level. To
date no trial, including JUPITER, has
been designed to answer the question
‘‘Does the use of hsCRP in clinical
practice result in reduced CVD outcomes
and improved health?’’ A meta-analysis
had already demonstrated that primary
prevention with statins lowers the risk of
CVD [18]. JUPITER might be considered
unique in that the study participants had a
reduced low-density lipoprotein (LDL) but
ASCOT-LLA (Anglo-Scandinavian Car-
diac Outcomes Trial–Lipid Lowering
Arm) has already demonstrated that
primary prevention patients at risk for
CVD benefit from a statin despite a lower
than ‘‘normal’’ LDL, albeit not as low an
LDL as was evaluated in JUPITER
(ASCOT-LLA mean LDL 3.4 mmol/l,
JUPITER median LDL 2.8 mmol/l)
[19]. It is important to remember that
JUPITER was an evaluation of a fixed
dose of rosuvastatin and thus getting
subjects to ‘‘targets’’ is purely extrapola-
tion, as none of the statin studies done to
Table 1. Estimated 10 year risk of a
heart attack, stroke, or other major
heart disease based on the risk
calculator at reynoldsriskscore.com.
Patient hsCRP mg/l
0.5 2 5 10
60 y/o male
a 13% 15% 16% 17%
70 y/o female
b 12% 15% 17% 19%
aNonsmoker, no family history, SBP 160 mmHg,
total cholesterol of 5 mmol/l and an HDL of
1 mmol/l.
bNonsmoker, no family history, SBP of 155 mmHg,
a total cholesterol of 6 mmol/l and an HDL of
1 mmol/l.
doi:10.1371/journal.pmed.1000196.t001
Table 2. Examples of drugs that lower hsCRP and the impact these drugs have had
on clinical outcomes.
Drug
Approximate % Decrease
in hsCRP [References]
Effect on Clinical
Outcomes
[References]
Rosiglitazone 40 [23] q [24]
Rofecoxib Q
a [25,26] q [27]
Fibrates 30–85 [23] « [28,29]
Vitamin E 50–80 [23] q« [30,31]
Niacin 25 [23] Q [32]
Ezetimibe 10 [33] « [34]
Statins 15–50 [23] Q [35]
q Consistent evidence is available that the drug increases the risk of cardiovascular events.
« Evidence is incomplete or inconsistent as to the effect the drug has on cardiovascular events.
Q Consistent evidence is available that the drug decreases the risk of cardiovascular events.
aRofecoxib reduces hsCRP more than placebo but not enough data is provided in the referenced studies to
give a specific % reduction.
doi:10.1371/journal.pmed.1000196.t002
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ally attempted to get subjects to a targeted
cholesterol or hsCRP level [20]. The
reductions in outcomes found in JUPI-
TER were greater than those seen in other
studies of statins in primary prevention.
For example, a meta-analysis of primary
prevention statin trials [18] found a 29.2%
reduction in relative risk for major coro-
nary events compared to 54% for the same
outcome in JUPITER [1]. It is tempting to
think the enrollment of patients with
hsCRP$2 mg/l contributed to the in-
creased benefit seen in JUPITER. How-
ever, JUPITER was stopped early for
benefit, and there is some suggestion that
trials stopped early for benefit yield
exaggerated treatment benefits [21]. Ad-
ditionally, it is important to keep in mind
the 54% reduction relative risk of major
coronary events is actually a 0.2% per year
absolute reduction (number need to treat
of 500) [1].
Is There Evidence That Baseline
hsCRP Levels Predict Outcomes
from Statin Therapy?
In a post-hoc analysis, Ridker et al.
reviewed participants in the AFCAPS/
TexCAPS study (Air Force/Texas Coro-
nary Atherosclerosis Prevention Study).
They stratified participants according to
their baseline LDLs or hsCRPs (A, any
hsCRP; H, LDL or hsCRP higher than
the median; L, LDL or hsCRP lower than
the median) to determine if different
baseline levels of hsCRP or LDL could
predict variations in the benefit of a statin.
The main results are outlined in Table 3.
Key issues to consider about the AF-
CAPS/TexCAPS data:
1. Only the L/L and the L/A groupings
showed a difference in baseline 5-year
risk.
2. In three of the categories (L/H, H/L,
and H/A), lovastatin produced a
reduction in events that was superior
to placebo; however, owing to the
overlapping CIs, no subset had a
statistically different magnitude of out-
come from any other subset.
3. Post-hoc analysis of subgroups defined
after randomization are subject to a
high risk of bias.
Isn’t There Evidence That
Reducing Levels of hsCRP
Predicts Outcomes?
The AFCAPS/TexCAPS retrospective
evaluation was about what happened to
subjects based on baseline LDL/hsCRP.
Interestingly, no studies have actually
looked prospectively at the question of
getting patients to a target hsCRP or
cholesterol. In the JUPITER study, a
fixed-dose rosuvasatin trial, investigators
did look at achieved (in contrast to
AFCAPS/TexCAPS) hsCRP and LDL
measurements to see if there was an
association between achieved levels and
outcome [22]. The categories they chose
(above or below an LDL of 1.8, an hsCRP
of 2 or 1) were prespecified. The key
findings are outlined in Table 4.
Key issues to consider about the JUPI-
TER data:
1. While some information about baseline
characteristics was provided, none was
provided for any of the subsets in
Table 4 other than the low LDL/low
hsCRP.
2. No information is provided regarding
how much (relatively) LDL and hsCRP
went down in each of the LDL/CRP
subsets.
3. Participants who took 20 mg of rosu-
vastatin and did not achieve an
LDL,1.8 or hsCRP,1 (H/H) experi-
enced no clinical benefit. While we are
not necessarily endorsing the ap-
proach, if one were to follow this
evidence, patients who do not attain
an LDL,1.8 and a hsCRP of less than
1 or 2 while on 20 mg of rosuvastatin
should stop taking the drug as they will
not derive a clinical benefit.
4. There is little difference in the results
among participants who achieved
hsCRP of ,1 mg/dl or ,2m g / d ,
which suggests that as long as you get
the hsCRP below 2 mg/dl any further
reduction yields no additional benefit.
5. Participants who achieved both an
LDL,1.8 and an hsCRP,2 (L/L),
had a lower point estimate of benefit
than participants who only achieved
one of these breakpoints. The authors
state that overall there was a p-value for
trend across LDL cholesterol and/or
hsCRP strata. However, the CIs for a
number of the groups clearly overlap to
a degree that does not allow one to
draw specific conclusions about the
differences in benefit between specific
subsets.
6. It is unknown if lower LDL/hsCRP
levels were attained due to differences
in adherence to rosuvastatin, a factor
that might help explain why the group
that did not achieve specific LDL and
hsCRP levels did not appear to benefit
from statin therapy.
Conclusion
The substantial intra-subject variation
in hsCRP measurements makes it virtually
impossible to assess the impact a therapy
has on hsCRP in an individual patient.
Even if the intra-subject variation is
ignored, when hsCRP is used in addition
to other established risk factors, the size of
Table 3. AFCAPS/TexCAPS acute coronary disease results - Relative risks (and 95% CIs) associated with lovastatin therapy,
according to baseline lipid and C-reactive protein levels.
LDL CRP Relative Risk of Acute Coronary Event 95% CI 5 Year Risk (%)
L L 1.08 0.56–2.08 2.2
L H 0.58 0.34–0.98 5.1
H L 0.38 0.21–0.70 5.0
H H 0.68 0.42–1.10 5.5
H A 0.53 0.37–0.77 5.3
L A 0.74 0.49–1.11 3.6
Data are from Table 2 in [36].
5 year risk (%), risk of an acute coronary event in the placebo arm group (in other words, this is a baseline risk for this population); A, any hsCRP; H, LDL or hsCRP higher
than the median; L, LDL or hsCRP lower than the median.
doi:10.1371/journal.pmed.1000196.t003
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even at the extremes of hsCRP levels, are
unlikely to change an individual’s decision
to seek therapy. Finally, the evidence that
cardiovascular events are reduced when a
patient takes a drug that lowers hsCRP is
inconsistent at best. Armed with this
information, we hope clinicians can deter-
mine for themselves whether measuring
hsCRP is an important part of a compre-
hensive risk profile or a clinically redun-
dant practice.
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